ACTG. 2007. Metabolic outcomes of ACTG 5142: A prospective, randomized Phase III trial of NRTI-, PI and NNRTI sparing Regimens for initial treatment of HIV-1. Presented at the 14th Conference on Retroviruses and Opportunistic Infections, February 25_28, Los Angeles
Bernasconi E., Boubaker K., Junghans C., Flepp M., Furrer H.J., Haensel A., et al. (2002). Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: The Swiss HIV cohort study. Journal Acquired Immune Deficiency Syndrome, 31, 50_55.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. [Accessed 12 December 2008]
Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, Butcher DL, Rooney JF, Haas DW, Mellors JW, Havlir DV; AIDS Clinical Trials Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment AIDS. 2009 Jun 1;23(9):1109-18.
Rajagopalan R, David Laitinen D, Dietz B. Impact of lipoatrophy on quality of life in HIV patients receiving anti-retroviral Therapy, AIDS Care, 2008 20:10,1197 - 1201
Santos C.P., Felipe Y.X., Braga P.E., Ramos D., Lima R.O., & Segurado A.C. (2005). Self-perception of body changes in persons living with HIV/AIDS: Prevalence and associated factors. AIDS, 19 (Suppl. 4), S14_21.